Daily Archives: November 11, 2021 | LinksMedicus Free Medical News & Perspectives

IDSA Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients with Suspected or Known COVID-19.

11 Nov, 2021 | 09:01h | UTC

Infectious Diseases Society of America Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients with Suspected or Known COVID-19

Commentary on Twitter

New recommendation on the use of eye protection as well as revised recommendations and literature on the use of PPE now available in IDSA’s COVID-19 Infection Prevention Guideline: https://t.co/MiACvSoG92 #COVID19Guidelines pic.twitter.com/Zp7s0Ely9J

— IDSA (@IDSAInfo) November 5, 2021

Podcast | COVID Updates: The Outpatient Edition.

11 Nov, 2021 | 08:57h | UTC

COVID Updates: The Outpatient Edition – The Curbsiders

Commentary on Twitter

Who gets a #COVID booster? Can we mix & match vaccines? What are monoclonal antibodies & when should we use them? Shots for kids? Ready yourself to answer these questions & more w/ @MonicaGandhi9 #vaccine #MedEd #FOAMed https://t.co/URrfwtuxVf pic.twitter.com/o26ElbPNaJ

— The Curbsiders (@thecurbsiders) November 8, 2021

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

11 Nov, 2021 | 08:59h | UTC

COVID antiviral pills: what scientists still want to know – Nature

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

M-A: Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19.

11 Nov, 2021 | 08:53h | UTC

Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19: a meta-analysis and GRADE assessment of cohort studies and RCTs – Nutritional Journal

Perspective | COVID’s endgame: Scientists have a clue about where SARS-CoV-2 is headed.

11 Nov, 2021 | 08:55h | UTC

COVID’s endgame: Scientists have a clue about where SARS-CoV-2 is headed – NPR

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.

11 Nov, 2021 | 08:52h | UTC

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2 – The Pediatric Infectious Diseases Journal

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

Consensus Statement: Advancing the global public health agenda for non-alcoholic fatty liver disease.

11 Nov, 2021 | 08:48h | UTC

Advancing the global public health agenda for NAFLD: a consensus statement – Nature Reviews Gastroenterology & Hepatology

Clinical Care Pathway for the Risk Stratification and Management of Patients with Nonalcoholic Fatty Liver Disease.

Non-alcoholic fatty liver disease: A patient guideline.

State of the art review: Management of non-alcoholic fatty liver disease

M-A: Non-alcoholic fatty liver disease linked to increased risk of fatal and non-fatal cardiovascular events.

M-A: non-invasive tests for advanced fibrosis can reduce the need for biopsy in patients with non-alcoholic fatty liver disease.

Review: Dietary carbohydrates and fats in nonalcoholic fatty liver disease.

Commentary on Twitter

A Consensus Statement published in @NatRevGastroHep discusses recommendations for tackling the burden of non-alcoholic fatty liver disease. https://t.co/eX7Ht53DOB pic.twitter.com/lHKsfQmSj3

— Nature Portfolio (@NaturePortfolio) November 6, 2021

RCT: In patients with acute stroke eligible for intravenous alteplase and endovascular treatment, intravenous alteplase before endovascular treatment did not improve outcomes compared to endovascular treatment alone.

11 Nov, 2021 | 08:43h | UTC

A Randomized Trial of Intravenous Alteplase before Endovascular Treatment for Stroke – New England Journal of Medicine (link to abstract – $ for full-text)

RCT: In patients with acute myocardial infarction complicated by a reduced left ventricular ejection fraction, pulmonary congestion, or both, Sacubitril–valsartan was not associated with improved outcomes compared to Ramipril.

11 Nov, 2021 | 08:44h | UTC

Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction – New England Journal of Medicine (link to abstract – $ for full-text)

Whole genome sequencing may improve the diagnosis of rare diseases and shorten diagnostic journeys for patients.

11 Nov, 2021 | 08:46h | UTC

News Release: Whole genome sequencing improves diagnosis of rare diseases and shortens diagnostic journeys for patients – Queen Mary University of London

Original Study: 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care — Preliminary Report – New England Journal of Medicine

RCT: Effect of whole-genome sequencing on the clinical management of acutely ill infants with suspected genetic disease.

Review: Genome sequencing as a diagnostic test.

RCT: Universal screening in high schools can help identify and initiate treatment for depression in adolescents.

11 Nov, 2021 | 08:35h | UTC

Screening in High Schools to Identify, Evaluate, and Lower Depression Among Adolescents: A Randomized Clinical Trial – JAMA Network Open

News release: School-based screening increases identification of, treatment for depression – Penn State

Commentaries:

Universal Depression Screening in Schools—Promises and Challenges in Addressing Adolescent Mental Health Need – JAMA Network Open

Universal School-Based Depression Screening May Connect More Students to Care – Psychiatric News Alert

Commentaries on Twitter

In a randomized clinical trial including 12,909 students at 14 Pennsylvania public high schools, adolescents randomized to receive a depression screen and identified with symptoms had 2.1 times higher odds of initiating depression treatment. https://t.co/b0l5ShCiHf pic.twitter.com/XptJDrH0Ne

— JAMA Network Open (@JAMANetworkOpen) November 8, 2021

M-A: Offspring’s risk for suicidal behavior in relation to parental death by suicide – “the experience of losing a parent to suicide is a strong and independent risk factor for suicidal behavior in offspring”.

11 Nov, 2021 | 08:39h | UTC

Offspring’s risk for suicidal behaviour in relation to parental death by suicide: systematic review and meta-analysis and a model for familial transmission of suicide – The British Journal of Psychiatry

Commentary on Twitter

Crucial question to ask all patients:
"Has anyone in your family committed suicide?"

Review of studies shows why: https://t.co/QIysuw9DoX

— Allen Frances (@AllenFrancesMD) November 10, 2021